Joseph Therriault
Overview
Explore the profile of Joseph Therriault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
2804
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leffa D, Povala G, Bellaver B, Ferrari-Souza J, Ferreira P, Lussier F, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e70003.
PMID: 39998851
Introduction: Epidemiological studies indicate a link between attention-deficit/hyperactivity disorder (ADHD) and elevated risk of dementia. However, the impact of ADHD on cognition and Alzheimer's disease (AD) biomarkers in individuals with...
2.
Arslan B, Brum W, Pola I, Therriault J, Rahmouni N, Stevenson J, et al.
Alzheimers Res Ther
. 2025 Feb;
17(1):48.
PMID: 39972340
Background: Impaired kidney function has a potential confounding effect on blood biomarker levels, including biomarkers for Alzheimer's disease (AD). Given the imminent use of certain blood biomarkers in the routine...
3.
Yun J, Shin D, Lee E, Kim J, Ham H, Gu Y, et al.
JAMA Neurol
. 2025 Feb;
PMID: 39960728
Importance: Understanding the characteristics of discordance between plasma biomarkers and positron emission tomography (PET) results in Alzheimer disease (AD) is crucial for accurate interpretation of the findings. Objective: To compare...
4.
Islam T, Hill E, Abrahamson E, Servaes S, Smirnov D, Zeng X, et al.
Nat Med
. 2025 Feb;
31(2):574-588.
PMID: 39930142
Patients with Alzheimer's disease (AD) with little or no quantifiable insoluble brain tau neurofibrillary tangle (NFT) pathology demonstrate stronger clinical benefits of therapies than those with advanced NFTs. The formation...
5.
Arias J, Brum W, Salvado G, Therriault J, Servaes S, Wang Y, et al.
Brain
. 2025 Jan;
PMID: 39879633
Plasma phosphorylated tau biomarkers open unprecedented opportunities for identifying carriers of Alzheimer's disease pathophysiology in early disease stages using minimally invasive techniques. Plasma p-tau biomarkers are believed to reflect tau...
6.
Wang Y, Ashton N, Therriault J, Benedet A, Macedo A, Pola I, et al.
Brain Commun
. 2025 Jan;
7(1):fcaf004.
PMID: 39845736
Blood-based biomarkers have been revolutionizing the detection, diagnosis and screening of Alzheimer's disease. Specifically, phosphorylated-tau variants (p-tau, p-tau and p-tau) are promising biomarkers for identifying Alzheimer's disease pathology. Antibody-based assays...
7.
Quispialaya K, Therriault J, Aliaga A, Benedet A, Ashton N, Karikari T, et al.
Neurology
. 2024 Dec;
104(2):e210211.
PMID: 39715476
Background And Objectives: To compare the diagnostic performance of an immunoassay for plasma concentrations of phosphorylated tau (p-tau) 217 with visual assessments of fluorine-18 fluorodeoxyglucose [F]FDG-PET in individuals who meet...
8.
Aumont E, Bedard M, Bussy A, Arias J, Tissot C, Hall B, et al.
Neurobiol Aging
. 2024 Dec;
146:48-57.
PMID: 39631245
In this longitudinal brain imaging study, we aimed to characterize hippocampal tau accumulation and subfield atrophy relative to cortical amyloid-β and memory performance. We measured tau-PET in regions associated with...
9.
Therriault J, Janelidze S, Benedet A, Ashton N, Arranz Martinez J, Gonzalez-Escalante A, et al.
Nat Aging
. 2024 Nov;
4(11):1529-1537.
PMID: 39533113
Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce...
10.
Woo M, Therriault J, Jonaitis E, Wilson R, Langhough R, Rahmouni N, et al.
EBioMedicine
. 2024 Nov;
109():105413.
PMID: 39500009
Background: Blood-based disease staging across the Alzheimer's disease (AD) continuum holds the promise to identify individuals that profit from disease-modifying therapies. We set out to identify Braak V (Braak V...